<- Go Home

Omega Pharma NV

Omega Pharma NV, together with its subsidiaries, engages in the development and sale of prescription-free health and personal care products to pharmacies and other medical sectors. The company offers personal care products for face and body, sun care products, and baby-specific products under the Bodysol/Galenco, ACO, Lactacyd, Claire Fisher, Bergasol, and Biodermal brand names; and medicated skin care products for various skin conditions and allergies under the Dermalex, Septivon, and Wartner brands. It also provides cough and cold products, and allergy products, as well as aromatherapy and homeopathic solutions under the Bittner/Aflubin, Prevalin/Beconase, Physiomer/Libenar, and Phytosun brand names; and anti-parasites under the Paranix and Jungle Formula brands for human, as well as Paravet/Clément-Thékan brand name for pets. In addition, the company offers vitamins, minerals, supplements, and natural remedies under the Davitamon, Biover, Abtei, Granufunk and Bional brand names; weight management products under the XLS and XLS Medical brands; pregnancy tests and self-diagnostic products under the Predictor brand name; pain relief products under the Solpadeine and Optalidon brands; eye care products under the Opticalm(ax) brand; and sleep aid products under the brand names of Silence and Nytol. It primarily operates in Belgium, France, Europe, Austria, Central and Eastern Europe, Australia, Argentina, and South-Africa. The company was founded in 1987 and is headquartered in Nazareth, Belgium. Omega Pharma NV operates as a subsidiary of Perrigo Company plc.

Market Cap

N/A

Volume

N/A

Cash and Equivalents

EUR 58.5M

EBITDA

EUR 122.2M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

EUR 566.0M

Profit Margin

57.31%

52 Week High

N/A

52 Week Low

N/A

Dividend

N/A

Price / Book Value

N/A

Price / Earnings

N/A

Price / Tangible Book Value

N/A

Enterprise Value

N/A

Enterprise Value / EBITDA

N/A

Operating Income

EUR 75.9M

Return on Equity

4.43%

Return on Assets

2.74

Cash and Short Term Investments

EUR 58.5M

Debt

EUR 316.9M

Equity

EUR 1.1B

Revenue

EUR 987.7M

Unlevered FCF

EUR 109.2M

Sector

Pharmaceuticals

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches